Supplementary Figure 14. Impact of the KEAPness-dominant phenotype in advanced NSCLC treated with chemotherapy (docetaxel) in the OAK/POPLAR trials
No takes yet. Share an insight, caveat, or question.
Scalera et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: